Trial Outcomes & Findings for The Self-Sampling Pilot Study (NCT NCT07085845)

NCT ID: NCT07085845

Last Updated: 2026-01-27

Results Overview

The presence of cells from the squamocolumnar junction will be assessed in each specimen (Yes/No). Proportions of specimens with squamocolumnar cells will be compared for the 5 cm and 3 cm swabs.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

Day 1

Results posted on

2026-01-27

Participant Flow

Participant milestones

Participant milestones
Measure
Intervention Arm
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus.
Control Arm
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus.
Overall Study
STARTED
23
27
Overall Study
COMPLETED
23
27
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Self-Sampling Pilot Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intervention Arm
n=23 Participants
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus.
Control Arm
n=27 Participants
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus.
Total
n=50 Participants
Total of all reporting groups
Age, Continuous
54.4 Years
STANDARD_DEVIATION 10.4 • n=25 Participants
56.1 Years
STANDARD_DEVIATION 11.6 • n=25 Participants
55.3 Years
STANDARD_DEVIATION 11.0 • n=50 Participants
Sex/Gender, Customized
Man
23 Participants
n=25 Participants
26 Participants
n=25 Participants
49 Participants
n=50 Participants
Sex/Gender, Customized
Trans Man
0 Participants
n=25 Participants
1 Participants
n=25 Participants
1 Participants
n=50 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=25 Participants
0 Participants
n=25 Participants
0 Participants
n=50 Participants
Race (NIH/OMB)
Asian
0 Participants
n=25 Participants
0 Participants
n=25 Participants
0 Participants
n=50 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=25 Participants
0 Participants
n=25 Participants
0 Participants
n=50 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=25 Participants
2 Participants
n=25 Participants
5 Participants
n=50 Participants
Race (NIH/OMB)
White
19 Participants
n=25 Participants
22 Participants
n=25 Participants
41 Participants
n=50 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=25 Participants
1 Participants
n=25 Participants
1 Participants
n=50 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=25 Participants
2 Participants
n=25 Participants
3 Participants
n=50 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=25 Participants
2 Participants
n=25 Participants
3 Participants
n=50 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants
n=25 Participants
25 Participants
n=25 Participants
46 Participants
n=50 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=25 Participants
0 Participants
n=25 Participants
1 Participants
n=50 Participants
Region of Enrollment
United States
23 Participants
n=25 Participants
27 Participants
n=25 Participants
50 Participants
n=50 Participants

PRIMARY outcome

Timeframe: Day 1

The presence of cells from the squamocolumnar junction will be assessed in each specimen (Yes/No). Proportions of specimens with squamocolumnar cells will be compared for the 5 cm and 3 cm swabs.

Outcome measures

Outcome measures
Measure
Intervention Arm
n=23 Participants
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus. Inserting a swab 5 cm into the anus during self-sampling: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
Control Arm
n=27 Participants
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus. Self-sampling with a swab by inserting the swab 3 cm into the anus.: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
Presence of Squamocolumnar Cells
Presence of squamocolumnar cells - Yes
11 Participants
8 Participants
Presence of Squamocolumnar Cells
Presence of squamocolumnar cells - No
12 Participants
19 Participants

SECONDARY outcome

Timeframe: Day 1

The presence of \~2000-3000 nucleated squamous cells will be assessed for cytologic adequacy (Yes/No). Proportions of adequate specimens will be compared for the 5 cm and 3 cm swabs.

Outcome measures

Outcome measures
Measure
Intervention Arm
n=23 Participants
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus. Inserting a swab 5 cm into the anus during self-sampling: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
Control Arm
n=27 Participants
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus. Self-sampling with a swab by inserting the swab 3 cm into the anus.: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
Cytologic Adequacy
Cytologic adequacy - No
3 Participants
8 Participants
Cytologic Adequacy
Cytologic adequacy - Yes
20 Participants
19 Participants

SECONDARY outcome

Timeframe: Day 1

Each participant will receive a short cytology CASI immediately after the cytology screening to rate their acceptability of the cytology screening on a Likert scale. Proportions of individuals' ratings for acceptability will be compared for the new NF swab vs the swab from the prior research.

Outcome measures

Outcome measures
Measure
Intervention Arm
n=23 Participants
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus. Inserting a swab 5 cm into the anus during self-sampling: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
Control Arm
n=27 Participants
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus. Self-sampling with a swab by inserting the swab 3 cm into the anus.: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
User Acceptability of New NF Swab Compared to Swab From Prior Research
Willing to do anal self-swabbing in the future - Strongly agree
13 Participants
21 Participants
User Acceptability of New NF Swab Compared to Swab From Prior Research
Willing to do anal self-swabbing in the future - Agree
10 Participants
6 Participants
User Acceptability of New NF Swab Compared to Swab From Prior Research
Willing to do anal self-swabbing in the future - Disagree
0 Participants
0 Participants
User Acceptability of New NF Swab Compared to Swab From Prior Research
Willing to do anal self-swabbing in the future - Strongly Disagree
0 Participants
0 Participants
User Acceptability of New NF Swab Compared to Swab From Prior Research
Willing to do anal self-swabbing in the future - Don't know
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Day 1

Each participant will receive a short cytology CASI immediately after the cytology screening to rate their pain during the cytology screening on a visual scale. Proportions of individuals' ratings for pain will be compared for the new NF swab vs the swab from the prior research.

Outcome measures

Outcome measures
Measure
Intervention Arm
n=23 Participants
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus. Inserting a swab 5 cm into the anus during self-sampling: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
Control Arm
n=27 Participants
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus. Self-sampling with a swab by inserting the swab 3 cm into the anus.: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
User Pain of New NF Swab Compared to Swab From Prior Research
No pain
12 Participants
15 Participants
User Pain of New NF Swab Compared to Swab From Prior Research
A little pain
9 Participants
10 Participants
User Pain of New NF Swab Compared to Swab From Prior Research
A little more pain
1 Participants
1 Participants
User Pain of New NF Swab Compared to Swab From Prior Research
Even more pain
1 Participants
1 Participants
User Pain of New NF Swab Compared to Swab From Prior Research
A whole lot of pain
0 Participants
0 Participants
User Pain of New NF Swab Compared to Swab From Prior Research
Worst pain
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Day 1

Each participant will receive a short cytology CASI immediately after the cytology screening to rate their pain during the cytology screening on a visual scale. Proportions of individuals' ratings for pain will be compared for the 5 cm and 3 cm swabs.

Outcome measures

Outcome measures
Measure
Intervention Arm
n=23 Participants
Individuals in the intervention arm will self-sample with a swab and insert the swab 5 cm into the anus. Inserting a swab 5 cm into the anus during self-sampling: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
Control Arm
n=27 Participants
Individuals in the control arm will self-sample with a swab and insert the swab 3 cm into the anus. Self-sampling with a swab by inserting the swab 3 cm into the anus.: The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
User Pain by Swab Length
No pain
12 Participants
15 Participants
User Pain by Swab Length
A little pain
9 Participants
10 Participants
User Pain by Swab Length
A little more pain
1 Participants
1 Participants
User Pain by Swab Length
Even more pain
1 Participants
1 Participants
User Pain by Swab Length
A whole lot of pain
0 Participants
0 Participants
User Pain by Swab Length
Worst pain
0 Participants
0 Participants

Adverse Events

Intervention Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Alan Nyitray, PhD

Medical College of Wisconsin

Phone: 414-955-7701

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place